Why Clarivate's Drugs to Watch 2026 Update Calls Retatrutide a Defining GLP-1 Drug
TL;DR: Clarivate's 2026 Drugs to Watch report projects retatrutide's 2028 launch and $30bn in 2031 sales across obesity and diabetes.
What Is Clarivate's Drugs to Watch 2026 Report?
Drugs to Watch is an annual analyst report published by Clarivate, a life-sciences data and analytics firm, identifying investigational or newly launched therapies its analysts expect to have the greatest clinical and commercial impact within five years. The 2026 edition, originally published 6 January 2026, named eleven candidates spanning oncology, immunology, rare disease and metabolic medicine.[1]
Among them, Eli Lilly's two cardiometabolic candidates — the oral GLP-1 receptor agonist orforglipron and the injectable triple agonist retatrutide — were singled out as the standout pair, described by Clarivate as exemplifying "the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior weight loss and expanded therapeutic applications spanning from brain health to renal disease."[2] Trade press revisited this analysis on 3 September 2026, with PharmExec running a piece describing the pair as the "defining GLP-1 drugs of the next decade," prompting renewed attention to Clarivate's underlying sales and launch projections.[3]
It is worth being precise about what this report is and is not. It is an independent analyst forecast, not a clinical trial result, not an FDA or MHRA decision, and not a company earnings statement. Clarivate builds its projections from published trial data, company guidance and its own commercial modelling — useful context for tracking where the GLP-1 field is heading, but not a substitute for the underlying TRIUMPH-1 Phase 3 data itself.
What Does Clarivate Project for Retatrutide's Launch Timeline?
2028: projected launches in the US (obesity and type 2 diabetes), UK and EU (obesity), and Japan (type 2 diabetes).[1]
2029: projected follow-on launches in the UK and EU for the type 2 diabetes indication.[1]
Basis: the timeline assumes Eli Lilly's own confirmed target of filing a Biologics License Application (BLA) with the FDA in Q1 2027, followed by a typical 10-12 month regulatory review.[4]
This estimate is consistent with what Velox has already tracked through Lilly's own disclosures: the company confirmed at its Q2 2026 earnings call that retatrutide's Phase 3 data package is complete, and separately confirmed a Q1 2027 BLA filing target after pushing the date back from an earlier guidance to allow more time for manufacturing and quality-control (CMC) data. Clarivate's 2028 launch estimate is simply what falls out of that filing date once a standard FDA review clock is applied — it is not based on any new trial readout.
A separate, unresolved variable sits underneath this timeline: whether the FDA ultimately classifies retatrutide as a drug (reviewed via an NDA) or a biological product (reviewed via a BLA), a dispute currently before the Seventh Circuit Court of Appeals, with oral arguments scheduled for 24 September 2026. Clarivate's launch model does not appear to account for delay risk from that litigation.
How Much Does Clarivate Project Retatrutide Will Sell by 2031?
Clarivate's model projects retatrutide will generate roughly $30.1 billion in combined 2031 revenue across G7 markets: about $10 billion from obesity indications and $20.1 billion from type 2 diabetes.[1] For comparison, orforglipron — Lilly's once-daily oral GLP-1 receptor agonist, and the first oral non-peptide GLP-1 drug to reach Phase 3 — is projected at roughly $16.3 billion (about $11.1 billion obesity, $5.2 billion diabetes) over the same period.[2]
| Metric | Retatrutide | Orforglipron |
|---|---|---|
| Route / dosing | Subcutaneous, once-weekly | Oral, once-daily |
| Mechanism | Triple GLP-1/GIP/glucagon agonist | Single-receptor GLP-1 agonist |
| Projected launch | From 2028 | Already MHRA-approved (UK) 10 Aug 2026 |
| Projected 2031 sales | ~$30.1bn | ~$16.3bn |
Figures as reported by Clarivate's Drugs to Watch 2026 analysis; for research reference only, not investment or medical guidance.
Clarivate frames the broader driver behind both figures as market growth: analysts cited in the same coverage put the overall cardiometabolic drug market at roughly $150 billion by 2035.[3] Retatrutide's larger individual projection reflects its wider late-stage evidence base — Phase 3 data now spans obesity (TRIUMPH-1), type 2 diabetes (TRANSCEND-T2D-1), knee osteoarthritis and obstructive sleep apnoea — a broader label ambition than a single-receptor oral drug typically carries.
Why Are Analysts Weighting the Triple-Agonist Mechanism So Heavily?
Three receptor pathways, one molecule
Retatrutide activates the GLP-1, GIP and glucagon receptors simultaneously, a mechanism explained in full in our retatrutide mechanism of action guide. Analysts treat this as the structural reason for retatrutide's larger reported effect sizes relative to single- or dual-receptor comparators.
Multiple Phase 3 readouts, not one
Unlike a newly filed drug with a single pivotal trial, retatrutide's forecast draws on a completed Phase 3 package across several indications, which Clarivate's analysts weigh as reducing single-trial risk in their model.
Still an investigational compound
Every figure in this report describes a product that has not yet been approved by the FDA, MHRA or EMA. Analyst sales models are estimates built years ahead of an actual launch and are routinely revised as trial, regulatory and litigation timelines shift.
An analyst forecast is not a clinical or regulatory outcome. Nothing in Clarivate's report changes retatrutide's current regulatory status: it remains an investigational compound, unapproved for human use anywhere in the world, pending Eli Lilly's planned Q1 2027 BLA filing and the unresolved Seventh Circuit classification dispute.
Does This Analyst Forecast Affect UK Research-Reagent Supply?
No. Clarivate's projections concern Eli Lilly's future licensed pharmaceutical product — the finished, injectable medicine the company plans to file for FDA approval in Q1 2027. That is an entirely separate category, supply chain and legal framework from the HPLC-verified retatrutide reagent Velox Peptides supplies to laboratories for in vitro study. See our guide on whether research peptides are legal in the UK for the regulatory distinction between a research reagent and a medicinal product.
Retatrutide is supplied by Velox Peptides as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Clarivate. Drugs to Watch 2026: retatrutide listing — projected launch timeline and 2031 sales estimate. clarivate.com
- Clarivate. Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report. Press release, 6 January 2026. clarivate.com
- PharmExec. Lilly's Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade. 3 September 2026. pharmexec.com
- CNBC. Eli Lilly will file for approval of retatrutide obesity drug in 2027. 23 July 2026. cnbc.com
- Velox Peptides. See our Q2 2026 Lilly earnings coverage and Q1 2027 BLA filing delay explainer for related regulatory-timeline context.
Frequently Asked Questions
What is Clarivate's Drugs to Watch 2026 report?
Drugs to Watch is Clarivate's annual analyst report identifying investigational and newly launched therapies it expects to have the largest clinical and commercial impact. The 2026 edition, originally published 6 January 2026, named eleven candidates, with Eli Lilly's orforglipron and retatrutide singled out as the standout cardiometabolic pair. Trade press including PharmExec recapped the analysis on 3 September 2026 under the headline "defining GLP-1 drugs of the next decade."
What does Clarivate project for retatrutide's launch timeline?
Clarivate's analysts model retatrutide launches beginning in 2028 in the US (obesity and type 2 diabetes), UK and EU (obesity) and Japan (type 2 diabetes), followed by UK and EU type 2 diabetes launches in 2029. This tracks Eli Lilly's own guidance of a Q1 2027 Biologics License Application filing, since a launch forecast sits roughly 12-18 months after a BLA is filed and reviewed.
How much does Clarivate project retatrutide will sell by 2031?
Clarivate's model projects retatrutide reaching approximately $30 billion in combined 2031 sales across G7 markets — about $10 billion from obesity indications and $20.1 billion from type 2 diabetes. This is an analyst forecast based on trial data and market modelling, not a company sales figure, a regulatory approval, or a guarantee of future performance.
How does retatrutide's projected sales figure compare to orforglipron's?
In the same report, Clarivate projects orforglipron — Eli Lilly's once-daily oral GLP-1 receptor agonist — will reach about $16.3 billion in combined 2031 sales ($11.1 billion obesity, $5.2 billion diabetes). Retatrutide's larger projected figure reflects its broader label ambitions (obesity, type 2 diabetes, sleep apnoea and knee osteoarthritis Phase 3 data) and its position as a triple GLP-1/GIP/glucagon receptor agonist rather than a single-receptor oral drug.
Does this analyst forecast affect Velox Peptides' UK research-reagent supply?
No. Clarivate's projections concern Eli Lilly's future licensed pharmaceutical product, which remains investigational and unapproved by the FDA or MHRA pending a Q1 2027 BLA filing. Velox Peptides supplies retatrutide as an HPLC-verified, batch-documented research reagent for in vitro laboratory use only, an entirely separate supply chain from any future licensed medicine Lilly may launch. Read the retatrutide research overview →